A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI.
A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI.
复制标题
DOI：
10.1162/153535003322750664
复制
发表时间：
2003-10-01
影响因子：
2.8
通讯作者：
Ross, Brian D
中科院分区：
文献类型：
--
作者：
Moffat, Bradford A;Reddy, G Ramachandra;Ross, Brian D
描述了一种新的聚丙烯酰胺超顺磁性氧化铁纳米颗粒平台，其已经被合成制备，使得氧化铁的多个晶体被封装在单个聚丙烯酰胺基质（聚丙烯酰胺磁性[PAM]纳米颗粒）内。该制剂提供了620和1140 sec（-1）mM（-1）之间的极大T2和T2* 弛豫率。将PAM纳米颗粒施用到具有原位9 L神经胶质瘤的大鼠中允许对血管系统、脑和神经胶质瘤中纳米颗粒的摄取进行定量药代动力学分析。不同大小（0.6，2，和10 kDa）的聚乙二醇添加到PAM纳米粒子的表面导致血浆半衰期的增加，并影响肿瘤的摄取和保留的纳米粒子，如定量的组织对比度的变化，使用MRI。这些纳米颗粒的灵活配方表明，未来的修改可以实现，允许其作为靶向分子成像造影剂和/或治疗平台用于多种适应症。
A novel polyacrylamide superparamagnetic iron oxide nanoparticle platform is described which has been synthetically prepared such that multiple crystals of iron oxide are encapsulated within a single polyacrylamide matrix (PolyAcrylamide Magnetic [PAM] nanoparticles). This formulation provides for an extremely large T2 and T2* relaxivity of between 620 and 1140 sec(-1) mM(-1). Administration of PAM nanoparticles into rats bearing orthotopic 9L gliomas allowed quantitative pharmacokinetic analysis of the uptake of nanoparticles in the vasculature, brain, and glioma. Addition of polyethylene glycol of varying sizes (0.6, 2, and 10 kDa) to the surface of the PAM nanoparticles resulted in an increase in plasma half-life and affected tumor uptake and retention of the nanoparticles as quantified by changes in tissue contrast using MRI. The flexible formulation of these nanoparticles suggests that future modifications could be accomplished allowing for their use as a targeted molecular imaging contrast agent and/or therapeutic platform for multiple indications.